Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A malignant fibroblastic neoplasm arising from the soft tissue. It is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma. 
Myxofibrosarcomas most frequently harbor alterations in TP53, CDKN2A, CDKN2B, ATRX, and RB1 .
CDKN2A Loss, CDKN2B Loss, TP53 Mutation, TP53 Loss, and TP53 c.217-c.1178 Missense are the most common alterations in myxofibrosarcoma .
There are 11 clinical trials for myxofibrosarcoma, of which 10 are open and 1 is completed or closed. Of the trials that contain myxofibrosarcoma as an inclusion criterion, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (5 open).
PIK3CA, PTEN, and RB1 are the most frequent gene inclusion criteria for myxofibrosarcoma clinical trials .
Doxorubicin, ipilimumab, and nivolumab are the most common interventions in myxofibrosarcoma clinical trials.
Significant Genes in Myxofibrosarcoma
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.